Close Menu

NEW YORK (GenomeWeb) – A multi-omics R&D outfit is commercializing a mass spectrometry-based blood test for metabolites indicative of cardiovascular disease caused by plaque buildup, or atherosclerosis. 

Global Genomics Group (G3) plans to develop the test, called knowPlaque, simultaneously as a laboratory-developed test (LDT) and as a US Food and Drug Administration-approved kit. The test looks at a multiplex set of metabolites and uses an algorithm to rule out patients for atherosclerosis.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.